SILVERARC CAPITAL MANAGEMENT, LLC
Position in DNTH — Dianthus Therapeutics, Inc. /DE/
CIK 1816307
BOSTON, MA
Position in DNTH
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$54,946,284
+$24,033,180 QoQ
Shares Held
654,746
-12.7% QoQ
Ownership
1.20%
of shares outstanding
% of Portfolio
6.49%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in DNTH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026SILVERARC CAPITAL MANAGEMENT, LLC holds $782,503,784 across 55 Biotechnology names. DNTH ranks #2 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KALV |
KalVista Pharmaceuticals, Inc.
|
2,876,407 | $57,902,072 | |
| 2 | DNTH |
Dianthus Therapeutics, Inc. /DE/
This page
|
654,746 | $54,946,284 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,314,189 | $50,583,134 | |
| 4 | CELC |
Celcuity Inc.
|
357,903 | $40,851,048 | |
| 5 | IMNM |
Immunome Inc.
|
1,850,278 | $40,465,579 | |
| 6 | KOD |
Kodiak Sciences Inc.
|
991,930 | $37,812,371 | |
| 7 | NUVL |
Nuvalent, Inc.
|
354,914 | $36,360,939 | |
| 8 | ABVX |
Abivax S.A.
|
302,530 | $33,686,715 |
All Filings in DNTH
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $54,946,284 | 654,746 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $30,913,104 | 750,136 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $26,559,912 | 674,966 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,784,865 | 95,806 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,452,658 | 190,334 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||